BACKGROUND: Although the occurrence of @entity3052 ( @entity3052 ) after chemotherapy for @entity1582 ( @entity1582 ) is common in clinical settings, the simultaneous occurrence of these @entity5 in @entity1 without previous exposure to chemotherapy is a rare event. Etiology, disease management, and clinical treatment remain unclear for this particular occurrence. To the best of our knowledge, this study is the first to report a case of simultaneous presentation of @entity3052 and @entity1582 after exposure to ultraviolet irradiation. CASE PRESENTATION: We reported the case of a 73-year-old @entity1 (Han Chinese ethnicity) without previous medical history of @entity3052 and @entity1582 . The morphology and immunology of bone marrow cells confirmed the co-existence of @entity3052 and @entity1582 . Fluorescent in situ hybridization analysis of immunomagnetically separated abnormal plasma cells showed abnormal expression of the amplified @entity996 , @entity876 , and @entity30291 (1p32). Cytogenetic analysis demonstrated Y chromosome deletion. After the @entity1 was administered with @entity1749 combined with @entity2592   +   @entity30021   +   @entity1261 (CAG regimen), and evident curative effects were observed. The @entity1 achieved and maintained complete remission for more than 6  months. Prior to the disease occurrence, the @entity1 had received ultraviolet irradiation for 1  year and was detected with aberrant gene expression of @entity996 , @entity876 , and @entity30291 (1p32). Nevertheless, the correlation of this phenomenon with the etiology of concurrent @entity3052 with @entity1582 remains unclear. CONCLUSION: This study discussed the case of a @entity1 diagnosed with @entity3052 concurrent with @entity1582 , who has no previous exposure to chemotherapy. This @entity1 was successfully treated by @entity1749 combined with CAG regimen. This study provides a basis for clinical treatment guidance for this specific group of @entity1 and for confirmation of the disease etiology.

A case of simultaneous occurrence of XXXX and @entity1582 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor'] @entity30021 :: ('MESH:D015250', 'Chemical') :: ['aclarubicin'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies'] @entity996 :: ('5925', 'Gene') :: ['RB-1'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM'] @entity876 :: ('7157', 'Gene') :: ['TP53'] @entity30291 :: ('1031', 'Gene') :: ['CDKN2C'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib']
@entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']
